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Stat3-Targeted Therapies Overcome the Acquired
Resistance to Vemurafenib in Melanomas
Fang Liu1,2,5, Juxiang Cao1,5, Jinxiang Wu1, Kayleigh Sullivan1, James Shen1, Byungwoo Ryu1, Zhixiang Xu3,
Wenyi Wei4 and Rutao Cui1
Vemurafenib (PLX4032), a selective inhibitor of Braf, has been approved by the US Food and Drug Administration
for the treatment of unresectable or metastatic melanoma in patients with BrafV600E mutations. Many patients
treated with vemurafenib initially display dramatic improvement, with decreases in both risk of death and tumor
progression. Acquired resistance, however, rapidly arises in previously sensitive cells. We attempted to overcome
this resistance by targeting the signal transducer and activator of transcription 3 (STAT3)–paired box homeotic
gene 3 (PAX3)-signaling pathway, which is upregulated, owing to fibroblast growth factor 2 (FGF2) secretion or
increased kinase activity, with the BrafV600E mutation. We found that activation of Stat3 or overexpression of PAX3
induced resistance to vemurafenib in melanoma cells. In addition, PAX3 or Stat3 silencing inhibited the growth of
melanoma cells with acquired resistance to vemurafenib. Furthermore, treatment with the Stat3 inhibitor,
WP1066, resulted in growth inhibition in both vemurafenib-sensitive and -resistant melanoma cells. Significantly,
vemurafenib stimulation induced FGF2 secretion from keratinocytes and fibroblasts, which might uncover, at
least in part, the mechanisms underlying targeting Stat3–PAX3 signaling to overcome the acquired resistance to
vemurafenib. Our results suggest that Stat3-targeted therapy is a new therapeutic strategy to overcome the
acquired resistance to vemurafenib in the treatment of melanoma.
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INTRODUCTION
Braf is a serine–threonine-specific protein kinase and an
isoform of Raf. Raf proteins (Raf-1, Araf, and Braf) are
intermediates in the Ras and MAPK signaling pathways and
affect cell proliferation (Fecher et al., 2007). Braf mutations are
the most prevalent somatic genetic events in human
cutaneous melanoma, occurring in 40–60% of metastatic
melanoma (Chin et al., 2006). Most Braf melanoma
mutations are within the kinase domain, with a single
substitution (V600E), accounting for 80% of the Braf
melanoma mutations (Brose et al., 2002; Davies et al.,
2002; Pollock and Meltzer, 2002). The mutant BrafV600E
protein possesses 10.7-fold increased kinase activity,
compared with wild-type Braf (Davies et al., 2002).
Currently, selective inhibitors of Braf, such as vemurafenib
(Bollag et al., 2010; Chapman et al., 2011; Flaherty et al.,
2010) and GSK2118436 (Flaherty and McArthur, 2010), have
demonstrated remarkable clinical activity in patients with
melanoma, and vemurafenib has recently been approved by
the US Food and Drug Administration for the treatment of
patients with unresectable or metastatic melanoma with
BrafV600E mutations (Chapman et al., 2011). Vemurafenib
was associated with a 63% relative reduction in the risk of
death and a 74% reduction in the risk of tumor progression in
patients with previously untreated, unresectable stage IIIC or
stage IV melanoma with BrafV600E mutations (Chapman et al.,
2011). Although the initial response to these drugs is profound,
it is temporary. Drug resistance frequently appears after only
6–9 months of therapy (Poulikakos and Rosen, 2011). This
type of ‘‘acquired resistance’’ develops after the melanomas
were originally sensitive to vemurafenib. Acquired resistance
has emerged as the major hurdle, preventing vemurafenib
from having a truly transformative impact on patients
with unresectable or metastatic melanoma with BrafV600E
mutations.
One potential solution to overcome the acquired resistance
of vemurafenib in patients with melanoma is to develop
combination-targeted therapies. One possible approach is
targeting a frequently altered pathway together with one of
the essential pathways in normal pigment cells. This strategy
could simplify patient selection, because the status of only one
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molecularly altered pathway is required for choosing the most
appropriate therapy. In addition, this therapy strategy would
reduce the potential toxicities, as lower drug doses could be
utilized to target the essential pathway. One prospective
candidate of the essential pathway in melanocytes is the
paired box homeotic gene 3 (PAX3) signaling cascade.
PAX3 is essential for maintaining melanocytic progenitor
cells (Scholl et al., 2001; Blake and Ziman, 2005;
Steingrimsson et al., 2005). A chromosomal deletion, a
splice-site mutation and an amino-acid substitution within
PAX3 cause Splotch-retarded, Splotch and Splotch-delayed
genetic mouse mutants, respectively, (Tassabehji et al., 1994).
Splotch-delayed homozygous mice survive to birth compared
with Splotch mutant mice, which die at E13 owing to neural
tube defects (Moase and Trasler, 1992). Heterozygous
Splotch-delayed (Splotch/þ ) mice display pigmentation
abnormalities characterized by abdominal white patches due
to defective neural crest-derived melanocyte development
(Epstein et al., 1993). PAX3 mutations result in humans to
produce type I and type III Waardenburg syndromes
(Tassabehji et al., 1992; Read and Newton, 1997),
conditions characterized by melanocyte deficiencies in the
skin and inner ear.
Our previous work has demonstrated that Stat3 binds to the
PAX3 upstream regulatory regions to transactivate the PAX3
promoter, resulting in constitutive PAX3 expression in mela-
nocytes in vivo and increased melanocyte numbers (Dong
et al., 2012). Although no small molecules are currently
available to directly target PAX3 transcription factor, Stat3-
targeted therapies are being evaluated in clinical trials for
several types of tumors (Darnell, 2005). We therefore
investigated whether Stat3 inhibition could be used to
overcome the acquired resistance to vemurafenib in
melanoma.
RESULTS
Stat3–PAX3 signaling is activated by BrafV600E or N-RASQ61K in
melanoma cells
In the case of vemurafenib resistance, certain N-RAS muta-
tions have been implicated (Nazarian et al., 2010). Thus, a
plethora of additional agents are needed to continue therapy.
To characterize the connection of vemurafenib resistance and
Stat3–PAX3 signaling in melanocytes, we introduced
N-RASQ61K or BrafV600E mutations into genetically modified
human melanocytes (hTERT/CDK4(R24C)/p53DD melano-
cytes) (Garraway et al., 2005) and measured phospho-Stat3
protein as well as PAX3 mRNA and protein levels at 48 hours
after introduction of N-RASQ61K or BrafV600E. We observed a
nearly 5-fold induction of PAX3 mRNA, accompanied by a
marked induction of phospho-Stat3 and PAX3 protein
expression after the infection with N-RASQ61K virus or
BrafV600E virus (Figure 1). These results suggest that activation
of Stat3 and upregulation of PAX3 are downstream targets of
mutant N-RASQ61K or BrafV600E in melanoma cells.
Vemurafenib resistance in melanoma cell lines
To identify whether Stat3–PAX3-targeted therapy is an effec-
tive strategy to overcome the acquired resistance to
vemurafenib, we generated vemurafenib-resistant A375
(A375R) and UACC62 (UACC62R) melanoma cells. A375
and UACC62 melanoma cells both harbor the BrafV600E
mutation, and both are sensitive to vemurafenib treatment
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Figure 1. Introduction of BrafV600E or N-RASQ61K activates Stat3–paired box
homeotic gene 3 (PAX3) signaling in melanocytes. Genetically engineered
human melanocytes (hTERT/p53DD/CDK4(R24C)) were infected with Ad-N-
RASQ61K, Ad-BrafV600E, or Ad-GFP. RNA and protein were collected at
24 hours after infections. (a) The mRNA expression of PAX3 was measured by
quantitative reverse transcriptase–PCR (RT-PCR) and normalized to
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Results are expressed
as the mean of the experiment done in triplicate±SEM. Induction is calculated
relative to PAX3 levels in vehicle-treated cells. (b) Protein expressions of Stat3,
phospho-Stat3, and PAX3 were analyzed by western blot along with tubulin,
which served as a loading control.
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(Supplementary Figure 1). Drug-resistant A375 and UACC62
cells were generated through treatment with increasing con-
centrations of vemurafenib (Nazarian et al., 2010; Villanueva
et al., 2010) (Supplementary Figure 1 online). The IC50’s of
parental A375 and UACC62 were 70 and 90 nM, respectively.
As expected, we found that the vemurafenib-resistant cells
required higher doses of vemurafenib for partial growth inhibi-
tion; the IC50’s of A375R and UACC62R were 4.4 and 5.1mM,
respectively, (Supplementary Figure 1B and C). Cell cycle
analysis demonstrated that treatment with 90 nM of vemurafenib
induced G0/G1 cell cycle arrest after 24 hours in parental cells,
but this level of vemurafenib did not effect in the vemurafenib-
resistant cells (Supplementary Figure 1C online).
Vemurafenib treatment represses Stat3–PAX3 signaling in
vemurafenib-sensitive melanoma cells
The activation of Stat3–PAX3 signaling is induced upon
infection with Ad-RASQ61K or Ad-BrafV600E adenoviral vectors
(Figure 1). Next, we examined the effect of vemurafenib on
Stat3–PAX3 signaling in vemurafenib-sensitive and -resistant
melanoma cells. The expression of phospho-Stat3 and PAX3
was detected in vemurafenib-stimulated parental and resistant
A375 and UACC62 melanoma cells (Figure 2). We found that
the activation of Stat3 and the protein expression of PAX3
were both repressed in vemurafenib-sensitive (parental) A375
and UACC62 melanoma cells, but higher vemurafenib con-
centration were required in resistant A375 and UACC62
melanoma cells. Specifically, vemurafenib at 1mM inhibited
the expression of phospho-Stat3 in sensitive cells, but not in
resistant cells (Figure 2). These results suggest that inhibition of
Stat3 signaling represents a potential therapeutic strategy to
overcome the acquired resistance to vemurafenib in mela-
noma cells.
PAX3 or Stat3 overexpression inhibits the sensitivity of
melanoma cells to vemurafenib
To further characterize the connection of vemurafenib resis-
tance and Stat3–PAX3 signaling in melanoma cells, we
introduced pcDNA-3.1-Stat3-CA (Ginsberg et al., 2007) or
PECE-PAX3 plasmids into A375 and UACC62 parental cells
and then measured the response of these cells to vemurafenib.
Introduction of pcDNA-3.1-Stat3-CA results in overexpression
of constitutively active Stat3 because of cysteine residues at
A661 and N663 of Stat3 (Ginsberg et al., 2007; Dai et al.,
2011). The IC50’s of A375-sensitive cells with Stat3 or
phospho-PAX3 overexpression were 2.3 and 3.7mM,
respectively. The IC50’s of UACC62-sensitive cells with
phospho-Stat3 or PAX3 overexpression were 3.6 and 4.7mM,
respectively, (Figure 3c). These results indicate that A375 and
UACC62 cells were resistant to vemurafenib treatment after
phospho-Stat3 or PAX3 introduction.
PAX3 or Stat3 silencing inhibits the growth of resistant
melanoma cells
To examine whether inhibition of Stat3–PAX3 signaling could
be a therapeutic strategy to overcome the acquired resistance
to vemurafenib in melanoma cells, Stat3 or PAX3 expression
was silenced in A375 and UACC62 vemurafenib-resistant
cells (Figure 4a and b). We found that knockdown of PAX3
and Stat3 expression significantly inhibited melanoma cell
growth (Figure 4c). Taken together, the phospho-Stat3 and
PAX3 expression studies and the Stat3- and PAX3-silencing
experiments both indicate that Stat3–PAX3 signaling repre-
sents a target for overcoming acquired vemurafenib resistance
in melanoma cells.
Vemurafenib treatment induces FGF2 secretion from melanoma
cells and stromal cells
A recent report demonstrates that tumor drug resistance is
caused, at least in part, by factors secreted by the tumor micro-
environment (Straussman et al., 2012). Secreted fibroblast
growth factor (FGF2) signaling has an important role in the
activation of Stat3–PAX3 signaling in melanocytes (Dong
et al., 2012). To examine whether FGF2 secretion is induced
by vemurafenib treatment in melanoma cells, FGF2 levels
were monitored in growth media from cultured parental and
vemurafenib-resistant melanoma cells. Cells were grown for
48 hours at 80% confluence in serum-free media and FGF2
was assayed in growth media, using an ELISA FGF2 kit
(F4210–19, US Biologic Marblehead, Marblehead, MA). We
found that secreted FGF2 levels were higher in vemurafenib-
resistant melanoma cells compared with vemurafenib-
sensitive (parental) cells (Figure 5a). In addition, both primary
keratinocytes and fibroblasts were treated with different doses
of vemurafenib. Culture media was collected and FGF2 levels
were determined by ELISA (Figure 5b). We found that FGF2
secretion was induced by vemurafenib treatment in a dose-
dependent manner. FGF2 has well-documented proliferative
activities and transduces signals via FGF receptors (Jaye et al.,
1992). Multiple studies have shown that FGF2 treatment can
induce proliferation of melanocytes in vitro (Halaban et al.,
1988; Imokawa et al., 1992) as well as in pigmented lesions in
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Figure 2. Stat3 is activated in melanoma cells with acquired resistance to
vemurafenib. Sensitive and resistant A375 (a) and UACC62 (b) melanoma cells
were stimulated by different doses of vemurafenib as indicated. Total protein
was collected 6 hours after stimulation. Protein expressions of phospho–ERK1/2,
Stat3, phospho-Stat3, and paired box homeotic gene 3 (PAX3) were analyzed
by western blot along with tubulin, which served as a loading control.
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grafts (Berking et al., 2001). Our previous work demonstrated
that secreted FGF2 from keratinocytes activates Stat3 in
melanocytes. Mechanistically, Stat3 binds to PAX3 upstream
regulatory sequences resulting in constitutive PAX3 expression
and increased numbers of melanocytes (Dong et al., 2012).
In this study, we found higher levels of secreted FGF2
in vemurafenib-resistant melanoma cells compared
with vemurafenib-sensitive melanoma cells. In addition,
vemurafenib stimulation induced FGF2 secretion from both
keratinocytes and fibroblasts. We postulate that Stat3–PAX3-
mediated vemurafenib resistance involves FGF2 secreted by
the tumor micro-environment (Figure 5c).
Stat3-targeted therapy overcomes the acquired resistance to
vemurafenib in melanomas
We have demonstrated that silencing Stat3–PAX3 signaling
inhibits the growth of vemurafenib-resistant cells (Figure 4).
This suggests that Stat3–PAX3-targeted treatment could be a
new therapeutic strategy to overcome the acquired resistance
to vemurafenib. To date, small molecules that target the PAX3
transcription factor are not available. In contrast, Stat3-
targeted therapies are well established (Levy and Inghirami,
2006) and, in fact, several small molecules targeting Stat3 are
currently being evaluated for head and neck tumors in
Phase I/II clinical trials (clinicaltrials.gov), including the
reagent WP1066 (Verstovsek et al., 2008). To examine
whether Stat3-targeting reagents can overcome melanoma
acquired resistance to vemurafenib, we tested the effect of
WP1066 on vemurafenib sensitivity of melanoma. We found
that WP1066 blocked Stat3 signal activation by inhibiting the
phosphorylation of Stat3 and repressing of PAX3 protein
expression in both parental and vemurafenib-resistant
melanoma cells (A375 and UACC62; Figure 6a). Consistent
with this, Stat3–PAX3 inhibition by WP1066 resulted in
growth inhibition (Figure 6b) in parental and resistant A375
and UACC62 melanoma cells. The IC50’s of parental A375
and UACC62 cells were 2.5 and 3.4mM, respectively. The
IC50’s of resistant A375 and UACC62 cells were 2.5 and
3.5mM, respectively, which are similar to the IC50’s of parental
A375 and UACC62 cells. We next evaluated the growth
inhibitory potential of combining vemurafenib and WP1066 in
vemurafenib-resistant cells. As shown in Figure 6c, cell growth
was more significantly inhibited by combining WP1066 (2mM)
and vemurafenib (200 nM) treatments together, compared with
either agent on its own. Thus, combination therapy with
WP1066 and vemurafenib can overcome the acquired resis-
tance to vemurafenib.
We also investigated the effects of Stat3 inhibition on cell
growth in three other vemurafenib-resistant cells: M249R,
M263R, and M308R (Nazarian et al., 2010). Naturally
occurring vemurafenib resistance arose in both M263R and
M308R cells and a specific N-RAS mutation gave rise to
vemurafenib resistance in M249R cells (Nazarian et al., 2010).
To confirm that inhibition of Stat3 is a new therapeutic
strategy to overcome the acquired resistance to vemurafenib
in melanoma cells, we first silenced the expression of Stat3 in
M263R and M249R cells (Figure 6d). The IC50’s of vemur-
afenib in M263R resistant cells with stable shStat3 was 46 nM
and the IC50 of vemurafenib in M249R cells with stable
shStat3 was 58 nM (Figure 6e). These results indicate that PAX3
or Stat3 silencing inhibits the growth of M263R and M249R
cells. We also found that WP1066 treatment resulted in
growth inhibition in M263R, M249R, and M308R cells
(Figure 6b). The vemurafenib IC50’s in M249R, M263R, and
M308R cells were 2.3, 2.3 and 3.9mM, respectively. These
results are consistent with the effects of WP1066 on parental
and vemurafenib-resistant A375 and UACC62 melanoma cells
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Figure 3. Overexpression of paired box homeotic gene 3 (PAX3) or Stat3
inhibits the response of melanoma cells to vemurafenib. A375 and UACC62
parental cells with pcDNA-3.1-Stat3-CA plasmids or PECE-PAX3 plasmids
introduction were stimulated with different doses of vemurafenib as indicated.
Total protein was collected 6 hours after stimulation. Protein expressions of
Stat3 and PAX3 were analyzed by western blot along with tubulin, which
served as a loading control. (a) A375 cells and (b) UACC62 cells. (c) Melanoma
cell growth was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-
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the ratio of treated to untreated cells at each dose for each replicate.
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and suggest that inhibition of Stat3–PAX3 signaling by
WP1066 is an effective therapeutic strategy to overcome
acquired resistance to vemurafenib.
To identify whether PAX3 repression is required in
WP1066-induced growth inhibition in resistant melanoma
cells, we introduced PECE-PAX3 plasmids into A375- and
UACC62-resistant cells and then evaluated the growth inhibi-
tory potential of combining vemurafenib and WP1066. As
shown in Figure 6f and g, cell growth was inhibited by
combining WP1066 (2mM) and vemurafenib (200 nM)
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treatment together in A375- and UACC62-resistant melanoma
cells, but higher vemurafenib concentration were required
(500 nm) in resistant A375 and UACC62 melanoma cells with
PAX3 overexpression.
DISCUSSION
Vemurafenib received Food and Drug Administration
approval for the treatment of late-stage melanoma on 17
August 2011. Unfortunately, de novo and acquired resistance
to vemurafenib are common (Chapman et al., 2011).
Therefore, it is important to understand vemurafenib
resistance mechanisms and identify potential therapeutic
strategies that could overcome this resistance. In the case of
vemurafenib resistance, PDGFRb upregulation, N-RAS
mutation (Nazarian et al., 2010) and increased MAP3K8/
COT activity (Johannessen et al., 2010; Wagle et al., 2011)
have all been implicated.
Drug combination therapies involving (1) Braf inhibitors and
MEK inhibitors (Basse et al., 2010; Bollag et al., 2010; Joseph
et al., 2010; Paraiso et al., 2010; Villanueva et al., 2010), (2)
PI3K/AKT/mTOR inhibitors (Dankort et al., 2009; Villanueva
et al., 2010; Shi et al., 2011), and (3) different
immunotheraptic reagents (Tsao et al., 2004; Hodi et al.,
2010) have all been studied in vitro. However, these
combination therapies would theoretically only be effective
in specific group of patients. In our present study, we
demonstrate that vemurafenib treatment represses Stat3–
PAX3 signaling in vemurafenib-sensitive melanoma cells, but
higher vemurafenib concentration are required in vemurafe-
nib-resistant melanoma cells. In addition, we show that
inhibition of Stat3–PAX3 signaling inhibits cellular growth in
melanoma cells with the acquired resistance to vemurafenib.
PAX3 is essential for maintaining melanocytic progenitor
cells (Scholl et al., 2001; Blake and Ziman, 2005;
Steingrimsson et al., 2005) and PAX3 overexpression is also
frequently detected in melanomas (Carreira et al., 1998; Barr
et al., 1999; Vachtenheim and Novotna, 1999; Scholl et al.,
2001; Abrahams et al., 2008; Plummer et al., 2008; Rodriguez
et al., 2008). Approximately 30–70% of primary melanoma
specimens and 77% of cultured primary melanoma cells
displayed PAX3 overexpression (Barr et al., 1999; Scholl
et al., 2001; Plummer et al., 2008; Yang et al., 2008).
However, the role of PAX3 in acquired resistance to
vemurafenib in melanoma is not known. Here, we
demonstrate that PAX3 silencing inhibits growth in
melanomas with acquired resistance to vemurafenib.
The Jak2-Stat3 pathway is emerging as a target of interest for
melanoma (Krasilnikov et al., 2003; Kortylewski et al., 2005;
Smalley and Herlyn, 2005). In malignant cells, Stat3 functions
in regulating cell proliferation, angiogenesis and inhibition of
apoptosis (Zushi et al., 1998; Catlett-Falcone et al., 1999;
Amin et al., 2004). Importantly, activation of Stat3 signaling is
a negative prognostic factor in human cutaneous melanoma
(Wang et al., 2007; Lee et al., 2012). In addition, the
antitumor effects of tyrosine isomers were mediated in part
by both inhibition of the MAP/ERK pathway and inactivation
of Stat3 signaling (Ruggiero et al., 2012). Here, we confirm
previous reports and demonstrate that vemurafenib treatment
repressed the activation of Stat3 in melanoma cells. We also
show that inhibition of Stat3 signaling inhibits cellular growth
in melanoma cells with acquired resistance to vemurafenib. A
previous report demonstrated that tyrosine phosphorylation of
Stat3/5 and of Jak2 was induced upon treatment of LU1205
melanoma cells with the MEK inhibitor PD98059 (Krasilnikov
et al., 2003). To further identify the connection between MEK
and Stat3 in melanoma cells, we silenced MEK1/2 expression
in B16-F10 cells and found that tyrosine phosphorylation of
Stat3 was repressed upon MEK1/2 silencing in B16-F10 cells
(Supplementary Figure 2 online). One possibility is that the
PD98059-mediated induction and activation of Stat3 signaling
in LU1205 melanoma cells is a cell and time-point specific.
WP1066 is a cell-permeable, AG 490 tyrphostin analog that
effectively inhibits the Jak2-Stat3 pathway (Hussain et al.,
2007) and subsequently inhibits the growth of malignant
glioma cells (Hussain et al., 2007), acute myelogenous
leukemia cells (Ferrajoli et al., 2007) and melanoma
cells (Kong et al., 2008). Previous reports have demon-
strated that WP1066 inhibits melanoma cell growth and
melanoma metastasis (Kong et al., 2008), and enhances
T-cell cytotoxicity against melanoma by inhibiting regulatory
T cells (Kong et al., 2009). A recent report shows that WP1066
enhanced the antitumor activity of cyclophosphamide in a
xenograft melanoma mouse models (Hatiboglu et al., 2012).
In this study, we demonstrate that WP1066 reduced cell
proliferation, and induced apoptosis and cell cycle arrest in
melanoma cells both with and without the acquired resistance
to vemurafenib. The IC50’s of WP1066 for cancer cells,
including the melanoma cells used here, range from 1.5–
5mmols (Kong et al., 2008; Kong et al., 2009). Although
WP1066 is currently being evaluated for head and neck
tumors and lymphoma in Phase I/II clinical trials
(clinicaltrials.gov), these high IC50 values would limit its
potential in a clinical setting. Therefore, new, more-sensitive
small molecules that target Stat3 need to be developed and
evaluated. However, these intriguing findings should
encourage the identification of other Stat3-targeting reagents
that could be useful in addressing the acquired resistance to
vemurafenib in melanoma.
MATERIALS AND METHODS
Cell lines and reagents
Primary keratinocytes and human foreskin fibroblasts were isolated
from normal discarded foreskins as described (Dunham et al., 1996;
Horikawa et al., 1996). Human primary keratinocytes were cultured
in keratinocyte serum-free medium (Invitrogen, Carlsbad, CA). A375
and UACC62 melanoma cells were generously provided by Dr David
Fisher (MGH, Harvard Medical School). M249R, M263R, and M308R
were generously provided by Dr Roger S. Lo and Dr Antoni Ribas
(UCLA) (Nazarian et al., 2010). All cells were cultured in DMEM
medium plus 10% fetal bovine serum. Immortal human melanocytes
(hTERT/p53DD/CDK4(R24C)) (Garraway et al., 2005) were cultured
in glutamine containing Ham’s F12 media supplemented with 7%
fetal bovine serum, 0.1 mM IBMX, 50 ng ml 1 TPA, 1mM Na3VO4,
and 1mM dbcAMP. Vemurafenib (PLX4032) was purchased from
Selleckchem (Houston, TX). WP1066 was purchased from Santa
Cruz (Santa Cruz, CA). pRetro-shStat3, pRetro-shPAX, pRetro-
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shMEK1, and pRetro-shMEK2 silencing vectors were purchased from
Cellogenetics (Ijamsville, MD). Plasmids pcDNA-3.1-Stat3-CA was
generously provided by Dr James E. Darnell (The Rockefeller
University, New York) (Ginsberg et al., 2007). PECE-PAX3 plasmids
were generously provided by Dr Michel Goossens. Lipofectamine
2000 (Invitrogen) was used in transfection. FGF2 ELISA kits were
purchased from Invitrogen.
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
assay of cell numbers
Ten thousand cells per well were plated in a 96-well plate.
Vemurafenib (PLX4032) or WP1066 was added to the growth media
after overnight culture and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide solution was added 72 hours later. Optical density
was read at 550 nm, and background was subtracted at 690 nm.
Flow cytometry
Cells were fixed in ice-cold 70% ethanol before DNA staining with
50mg ml 1 propidium iodide (Sigma Aldrich, St Louis, MO) in PBS
containing 0.1 mg ml 1 RNase (Amersham, Piscataway, NJ). DNA
content was analyzed by flow cytometry (Becton Dickinson FACS-
Calibur, Franklin Lakes, NJ).
Total RNA isolation, protein isolation, real-time reverse
transcriptase–PCR, western blotting, and enzyme immunoassay
Total RNA was isolated from melanocytes using TRIzol reagent
(Invitrogen). cDNA was synthesized with the SuperScript first strand
system (Invitrogen) using 2mg of total RNA as template and oligo(dT)
as primer. Total protein was extracted by in DOC buffer (Pierces
protein assay kit, Rockford, IL).
For quantitative reverse transcriptase–PCR, total RNA was con-
verted into cDNA using the SuperScript III reverse transcriptase kit
(Invitrogen). cDNA expression was measured using the QuantiTect
Probe reverse transcriptase–PCR kit (Qiagen, Valencia, CA) and the
ICycler detector (BioRad, Hercules, CA). Gene-specific primers are as
described (Dong et al., 2012).
Western blotting was performed using the following antibodies:
anti-PAX3 (The Developmental Studies Hybridoma Bank at the
University of Iowa); anti-p-Stat3 (Tyr705) (Cell Signaling, Danvers,
MA); anti-p-Stat33 (Ser727) (Cell Signaling); anti-Stat3 (9D8, Thermo
Scientific, Rockford, IL); anti-p-ERK1/2 (Cell Signaling); and anti-tubulin
(Sigma Aldrich). Enzyme immunoassay was performed using FGF2
ELISA kit (F4210–19, US Biologic Marblehead).
Statistical analysis
Experiments were independently carried out at least three times and
one representative data set out of the three independent experiments
was presented where appropriate. The results were evaluated for
statistical significance by student t-test or two-sample t-test. Error bars
were marked as the SD of the mean. P-values o0.05 were regarded
as significant.
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